By: E. Dewulf
During SABCS 2024, a number of abstracts were dedicated to the treatment of ductal carcinoma in situ (DCIS). A combined analysis of two trials investigated the impact of tamoxifen use on ipsilateral breast recurrence in patients with “good-risk” DCIS. In addition, the COMET trial provided data on the omission of surgical treatment for low-risk DCIS, by evaluating the impact on the short-term on both ipsilateral invasive breast recurrence and patient-reported outcomes (PROs).
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
